Asset profile

fecal microbiota spores, live-brpk · VOWST

Microbiome therapeutic

Approved / Phase 4Mechanism not established

Approvedregulatory verdict

Evidence outlook

Approved: Recurrent Clostridioides Difficile Infection

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Featured trials

Research

Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.

No competitors sharing a mechanism or indication in the current universe.

No upcoming readouts on record for this asset.

Research

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Research shows how much of each listed holder's unusual share-price movement fell on this asset's announcements. Unlock with Research ↗

(1)

Research

The public profile shows up to three recent subject announcements. Research adds the complete feed and separately labelled competitive mentions.

fecal microbiota spores, live-brpk (VOWST) is marketed by Seres Therapeutics.

Yes. fecal microbiota spores, live-brpk (VOWST) is approved in the US for Recurrent Clostridioides Difficile Infection (FDA, April 2023).